Jump to page content Accessibility
News, views and contacts from the global Drugdevelopment industry
Login to drugdevelopment-technology.com Log in or Register
  • Home
  • Products & Services
  • Company A - Z
  • Projects
  • Features
  • Videos
  • White Papers
  • News
  • Events
  • Advertise With Us
Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

Saxagliptin – Treatment for Type 2 Diabetes



Percentage of men and women in England classified as obese

The percentage of men and women in England classified as obese has been increasing over time.

  • Features common to people who develop type 2 diabetes
    Raised blood pressure and obesity are features common to people who develop...
  • Percentage of men and women in England classified as obese
    The percentage of men and women in England classified as obese has been...
  • Management of type 2 diabetes
    Management of type 2 diabetes requires maintenance of good glycaemic control...
  • characteristics of patients with type 2 diabetes
    Common characteristics of patients with type 2 diabetes.

Back to Project Details



Related Projects

Erbitux (Cetuximab)
Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for...

Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

Xolair - Biological Therapy
The product of a joint development programme between Tanox, Genentech...

Exanta - Oral Direct Thrombin Inhibitor for the
Exanta (ximelagatran) is an oral Direct Thrombin Inhibitor (DTI)...

Prexige - COX-2 Inhibitor
Prexige (lumiracoxib) is an innovative COX-2 inhibitor developed by...

See all projects


Follow Us:
Twitter Twitter    Facebook Facebook   
Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2012 Net Resources International, a trading division of SPG Media Limited.